{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-034814","form_type":"8-K","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.692049+00:00","generated_at":"2026-06-21T07:26:02.464774+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bioxytran receives CDSCO approval for Phase 1b/2a trial of ProLectin-M in COVID-19 patients","bullets":["IND authorization from India's CDSCO for a Phase 1b/2a randomized, blinded, placebo-controlled study of ProLectin-M in mild-to-moderate COVID-19.","Trial will evaluate safety, efficacy, and pharmacokinetics of oral ProLectin-M; results to guide a 408-patient Phase III trial.","Condition: each site must obtain Ethics Committee approval before starting enrollment.","Press release issued December 8, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-034814","json":"https://secwatch.observer/filing/0001493152-22-034814.json","markdown":"https://secwatch.observer/filing/0001493152-22-034814.md","text":"https://secwatch.observer/filing/0001493152-22-034814.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000149315222034814/0001493152-22-034814-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000149315222034814/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:26:02.464774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}